Prescription drug · NDA AUTHORIZED GENERIC
Lanthanum carbonate NDC 66993-422
Lanthanum carbonate 500 mg/1 · Tablet, Chewable · Oral · Prasco Laboratories
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 66993-422-85 | 6699304228566993042285 | 2 BOTTLE in 1 PACKAGE (66993-422-85) / 45 TABLET, CHEWABLE in 1 BOTTLE (66993-422-47)Marketed from Aug 30, 2017 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Lanthanum carbonate
- Generic name (nonproprietary)
- lanthanum carbonate
- Active ingredients
- Lanthanum carbonate — 500 mg/1
- Dosage form
- Tablet, Chewable
- Route
- Oral
- Labeler
- Prasco LaboratoriesNDC labeler code 66993
- Product type
- Prescription drug
- Marketing category
- NDA authorized genericApplication NDA 021468
- Marketing start
- Listing expires
- Other FDA classes
- Phosphate Chelating Activity (Mechanism)
- Identifiers
- Product ID 66993-422_bac21d2f-425d-46ab-ae15-e8cfb373615eSPL ID bac21d2f-425d-46ab-ae15-e8cfb373615eSPL set ID bb263fe8-2bdf-4dba-807f-194f54a73654RxCUI 477347, 602635, 642452UNII 490D9F069T
- Pharmacologic class
- Phosphate Binder
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N466993042285followed by a unit qualifier and the quantityPackage 66993-0422-85. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 66993-422
- What is NDC 66993-422?
- 66993-422 is the product NDC for Lanthanum carbonate, Lanthanum carbonate 500 mg/1 tablet, chewable, listed with the FDA by Prasco Laboratories. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Lanthanum carbonate.
- What is the active ingredient?
- Lanthanum carbonate.
- Who is the labeler?
- Prasco Laboratories, NDC labeler code 66993. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Lanthanum carbonate?
- 16 other product NDCs are listed under this name. See all Lanthanum carbonate NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Lanthanum carbonate products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Lanthanum Carbonate | Lanthanum carbonate 500 mg/1 | Tablet, ChewableOral | Ascend Laboratories, LLC | 67877-256 | 67877-0256-90 |
| Lanthanum Carbonate | Lanthanum carbonate 750 mg/1 | Tablet, ChewableOral | Ascend Laboratories, LLC | 67877-257 | 67877-0257-90 |
| Lanthanum Carbonate | Lanthanum carbonate 1000 mg/1 | Tablet, ChewableOral | Ascend Laboratories, LLC | 67877-258 | 67877-0258-90 |
| Lanthanum carbonate | Lanthanum carbonate 500 mg/1 | Tablet, ChewableOral | Teva Pharmaceuticals USA, Inc. | 0093-5938 | 00093-5938-98 |
| Lanthanum carbonate | Lanthanum carbonate 750 mg/1 | Tablet, ChewableOral | Teva Pharmaceuticals USA, Inc. | 0093-5939 | 00093-5939-98 |
| Lanthanum carbonate | Lanthanum carbonate 500 mg/1 | Tablet, ChewableOral | Cipla USA Inc. | 69097-934 | 69097-0934-98 |
| Lanthanum carbonate | Lanthanum carbonate 750 mg/1 | Tablet, ChewableOral | Cipla USA Inc. | 69097-935 | 69097-0935-98 |
| Lanthanum carbonate | Lanthanum carbonate 1000 mg/1 | Tablet, ChewableOral | Cipla USA Inc. | 69097-936 | 69097-0936-98 |
| Lanthanum carbonate | Lanthanum carbonate 500 mg/1 | Tablet, ChewableOral | Exelan Pharmaceuticals, Inc. | 76282-476 | 76282-0476-90 |
| Lanthanum carbonate | Lanthanum carbonate 750 mg/1 | Tablet, ChewableOral | Exelan Pharmaceuticals, Inc. | 76282-477 | 76282-0477-90 |
Other NDCs under NDA 021468
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Fosrenollanthanum carbonate | Lanthanum carbonate 500 mg/1 | Tablet, ChewableOral | Takeda Pharmaceuticals America, Inc. | 54092-252 |
| Fosrenollanthanum carbonate | Lanthanum carbonate 750 mg/1 | Tablet, ChewableOral | Takeda Pharmaceuticals America, Inc. | 54092-253 |
| Fosrenollanthanum carbonate | Lanthanum carbonate 1000 mg/1 | Tablet, ChewableOral | Takeda Pharmaceuticals America, Inc. | 54092-254 |
| Lanthanum carbonate | Lanthanum carbonate 750 mg/1 | Tablet, ChewableOral | Prasco Laboratories | 66993-423 |
| Lanthanum carbonate | Lanthanum carbonate 1000 mg/1 | Tablet, ChewableOral | Prasco Laboratories | 66993-424 |